All In Biotech

Drug Trial Radar · NCT04659707

Hyperpolarized 129Xe MRI of Survivors of COVID-19

Evaluating Lung Structure and Function in Survivors of COVID-19 Using Hyperpolarized 129Xe MRI

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Feb 22, 2021

Primary completion

Jan 1, 2025

Study completion May 1, 2025

Sponsor

Lead sponsor
University of Kansas Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate pulmonary function of patients recovering from mild, moderate, and severe COVID-19 disease using hyperpolarized 129Xe MRI.

Conditions

  • Covid19

Interventions

  • Hyperpolarized Xe129Drug

    Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ventilation Defect PercentageTime frame: Baseline
  2. Ventilation Defect PercentageTime frame: 6-months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Kansas Medical Center

    Kansas City, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.